MedTrace Logo

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

NCT07619287 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

Conditions

  • Myeloid Malignancy

Interventions

DRUG

BG-75202

Administered orally

DRUG

Hypomethylation Agent (HMA)

Administered Intravenous (IV) or Subcutaneous (SC)

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-23
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • Australia
  • China
  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619287 on ClinicalTrials.gov